Tirzepatide denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tirzepatide as Not FDA-Approved — and Why You Can Appeal

A "not FDA-approved" denial for tirzepatide from UnitedHealthcare requires careful reading of the denial letter. Tirzepatide holds FDA approval for specific indications. If UHC's denial says "not FDA-approved," it is most likely claiming either: (a) the specific indication for which it was prescribed is not an approved indication (i.e., off-label use), or (b) the denial language is a form letter error. Both situations are appealable, and in the case of an approved indication, the denial is factually incorrect on its face.

## Why This Denial Is Appealable

For an FDA-approved indication: the denial is incorrect and should be reversed. Document the FDA approval status and the indication under which tirzepatide was prescribed, and present this in the appeal with the current prescribing label. For an off-label use: most plan documents and state laws require coverage of off-label uses supported by recognized compendia (such as DrugDEX or AHFS) or substantial clinical evidence from peer-reviewed literature. Your prescriber can document the clinical basis and guideline-organization support for the off-label use.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 or applicable state law, you have the right to a full internal review. The deadline is on your denial letter — typically 180 days. Request the specific policy basis for the not-FDA-approved determination.
• External review: Under ACA §2719, this type of denial is eligible for independent external review after internal remedies are exhausted. The external-review window is generally within approximately four months of the final internal denial. External reviewers apply clinical-evidence standards.
• Expedited review: Available for urgent situations; typically decided within 72 hours.

## Concrete Appeal Steps

1. Read the denial letter carefully — identify whether UHC is calling tirzepatide itself not approved, or the specific indication. 2. Pull the current FDA-approved prescribing label for tirzepatide and confirm the approved indications. 3. If the prescribed use matches an approved indication, this is your primary argument — attach the label to the appeal. 4. If it is an off-label use, ask your prescriber to document the clinical basis and any applicable guideline-organization support. 5. Submit your internal appeal with the FDA label and prescriber letter. 6. If denied internally, immediately request external review — FDA approval documentation is highly persuasive to independent reviewers.

## Documentation to Gather

• FDA prescribing label: The current tirzepatide label showing approved indications — obtain from the FDA website or the manufacturer.
• Prescription and diagnosis records: Documentation that the prescribed indication matches the FDA-approved use (or, for off-label, the clinical basis).
• Prescriber letter: Addresses the FDA-approval question directly, confirms the indication, and provides clinical rationale.
• Guideline-organization support (if off-label): Reference to applicable guideline organizations (e.g., ADA, relevant obesity-medicine society) supporting the use.

## Criteria-Mapping Structure

Begin the appeal letter by stating the FDA-approved indication and attaching the prescribing label page. Then map the prescribed use to that approved indication verbatim. If UHC's denial cites a specific policy criterion, list each criterion and provide your evidence response. For off-label appeals, cite each applicable guideline or compendium reference your prescriber identifies, one per row, with the clinical rationale attached.